Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of HRS-4508 in combination with other antitumor therapies in non-small cell lung cancer
CTR20254157Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HRS-4508 in non-small cell lung cancer (NSCLC) and bronchial carcinoma, sponsored by Hengrui Therapeutics. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 3 more. Started Dec 2025; status: active.
02
Drugs
HRS-4508
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on CTR20254157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254157.